Table of Contents Author Guidelines Submit a Manuscript
Journal of Pregnancy
Volume 2018, Article ID 2632637, 23 pages
https://doi.org/10.1155/2018/2632637
Review Article

Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns

Centre for Molecular Medicine and Biobanking, Faculty of Medicine and Surgery, University of Malta, Msida MSD2080, Malta

Correspondence should be addressed to Byron Baron; moc.liamg@sbalnegna

Received 4 February 2018; Accepted 15 May 2018; Published 28 June 2018

Academic Editor: Fabio Facchinetti

Copyright © 2018 Maria Portelli and Byron Baron. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. K. Wagner, “Diagnosis and management of preeclampsia,” American Family Physician, vol. 70, no. 12, pp. 2317–2324, 2004. View at Google Scholar · View at Scopus
  2. S. Grill, C. Rusterholz, R. Zanetti-Dällenbach et al., “Potential markers of preeclampsia - A review,” Reproductive Biology and Endocrinology, vol. 7, article no. 70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Reddy, S. Suri, I. L. Sargent, C. W. G. Redman, and S. Muttukrishna, “Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia,” PLoS ONE, vol. 4, no. 2, Article ID e4453, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. P. Mackay, C. J. Berg, and H. K. Atrash, “Pregnancy-Related Mortality from Preeclampsia and Eclampsia,” Obstetrics & Gynecology, vol. 97, no. 4, pp. 533–538, 2001. View at Publisher · View at Google Scholar
  5. K. Braekke, P. M. Ueland, N. K. Harsem, and A. C. Staff, “Asymmetric dimethylarginine in the maternal and fetal circulation in preeclampsia,” Pediatric Research, vol. 66, no. 4, pp. 411–415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. W. Redman and I. L. Sargent, “Latest advances in understanding preeclampsia,” Science, vol. 308, no. 5728, pp. 1592–1594, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. B. SIBAI, G. DEKKER, and M. KUPFERMINC, “Pre-eclampsia,” The Lancet, vol. 365, no. 9461, pp. 785–799, 2005. View at Publisher · View at Google Scholar
  8. ACOG Committee on Practice Bulletins—Obstetrics, “ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia,” Obstetrics & Gynecology, vol. 99, no. 1, pp. 159–167, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. E. J. Roccella, “Report of the national high blood pressure education program working group on high blood pressure in pregnancy,” American Journal of Obstetrics & Gynecology, vol. 183, no. 1, pp. S1–S22, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Grima, M. Vella, and C. Savona-Ventura, “Hypertensive disorders during pregnancy in pre-gestational diabetic women,” Malta Medical Journal, vol. 22, no. 2, pp. 15–18, 2010. View at Google Scholar · View at Scopus
  11. A. Díaz Pérez, A. Roca Pérez, G. Oñate Díaz, P. Castro Gil, and E. Navarro Quiroz, “Interaction and dynamics of these risk factors in hypertensive disorders of pregnancy: a pilot study,” Salud Uninorte, vol. 33, no. 1, pp. 27–38, 2017. View at Publisher · View at Google Scholar
  12. G. Dekker and B. Sibai, “Primary, secondary, and tertiary prevention of pre-eclampsia,” The Lancet, vol. 357, no. 9251, pp. 209–215, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Lipstein, C. C. Lee, and R. S. Crupi, “A current concept of eclampsia,” The American Journal of Emergency Medicine, vol. 21, no. 3, pp. 223–226, 2003. View at Publisher · View at Google Scholar
  14. E. Nexø, “Clinical biochemistry,” FEBS Letters, vol. 375, no. 3, pp. 312-313, 1995. View at Publisher · View at Google Scholar
  15. K. Duckitt and D. Harrington, “Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies,” British Medical Journal, vol. 330, no. 7491, p. 565, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. J. P. Warrington, E. M. George, A. C. Palei, F. T. Spradley, and J. P. Granger, “Recent advances in the understanding of the pathophysiology of preeclampsia.,” Hypertension, vol. 62, no. 4, pp. 666–673, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. T.-H. Hung, J. N. Skepper, D. S. Charnock-Jones, and G. J. Burton, “Hypoxia-reoxygenation: A potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia,” Circulation Research, vol. 90, no. 12, pp. 1274–1281, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Soleymanlou, I. Jurisica, O. Nevo et al., “Molecular evidence of placental hypoxia in preeclampsia,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 7, pp. 4299–4308, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Roberts, “Is oxidative stress the link in the two-stage model of pre-eclampsia?” The Lancet, vol. 354, no. 9185, pp. 788-789. View at Publisher · View at Google Scholar
  20. U. D. Anderson, M. G. Olsson, S. Rutardttir et al., “Fetal hemoglobin and α1-microglobulin as first- and early second-trimester predictive biomarkers for preeclampsia,” American Journal of Obstetrics & Gynecology, vol. 204, no. 6, pp. 520–e5, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. G. J. Burton and E. Jauniaux, “Oxidative stress,” Best Practice & Research Clinical Obstetrics & Gynaecology, vol. 25, no. 3, pp. 287–299, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. K. May, L. Rosenlöf, M. G. Olsson et al., “Perfusion of human placenta with hemoglobin introduces preeclampsia-like injuries that are prevented by α1-microglobulin,” Placenta, vol. 32, no. 4, pp. 323–332, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. A. H. Shennan, L. Poston, L. C. Chappell, and P. T. Seed, “Prevention of pre-eclampsia,” The Lancet, vol. 357, no. 9267, p. 1534, 2001. View at Publisher · View at Google Scholar
  24. S.-Y. Kim, H.-M. Ryu, J.-H. Yang et al., “Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia,” Journal of Korean Medical Science, vol. 22, no. 5, pp. 873–877, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Madazli, E. Budak, Z. Calay, and M. F. Aksu, “Correlation between placental bed biopsy findings, vascular cell adhesion molecule and fibronectin levels in pre-eclampsia,” BJOG: An International Journal of Obstetrics & Gynaecology, vol. 107, no. 4, pp. 514–518, 2000. View at Publisher · View at Google Scholar
  26. N. Hadker, S. Garg, C. Costanzo et al., “Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: A decision-analytic modeling analysis from a UK healthcare payer perspective,” Journal of Medical Economics, vol. 13, no. 4, pp. 728–737, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. U. D. Anderson, M. G. Olsson, K. H. Kristensen, B. Åkerström, and S. R. Hansson, “Review: biochemical markers to predict preeclampsia,” Placenta, vol. 33, pp. S42–S47, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. P. von Dadelszen, L. A. Magee, and J. M. Roberts, “Subclassification of Preeclampsia,” Hypertension in Pregnancy, vol. 22, no. 2, pp. 143–148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Maglione, V. Guerriero, G. Viglietto, P. Delli-Bovi, and M. G. Persico, “Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 88, no. 20, pp. 9267–9271, 1991. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Hauser and H. A. Weich, “A heparin-binding form of placenta growth factor (plGF-2) is expressed in human umbilical vein endothelial cells and in placenta,” Growth Factors, vol. 9, no. 4, pp. 259–268, 1993. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Maglione, V. Guerriero, G. Viglietto et al., “Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14,” Oncogene, vol. 8, no. 4, pp. 925–931, 1993. View at Google Scholar · View at Scopus
  32. Y. Cao, W.-R. Ji, P. Qi, Å. Rosin, and Y. Cao, “Placenta growth factor: Identification and characterization of a novel isoform generated by RNA alternative splicing,” Biochemical and Biophysical Research Communications, vol. 235, no. 3, pp. 493–498, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. J. E. Park, H. H. Chen, J. Winer, K. A. Houck, and N. Ferrara, “Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR,” The Journal of Biological Chemistry, vol. 269, no. 41, pp. 25646–25654, 1994. View at Google Scholar · View at Scopus
  34. A. Ahmed, X. F. Li, C. Dunk, M. J. Whittle, D. I. Rushton, and T. Rollason, “Colocalisation of vascular endothelial growth factor and its flt-1 receptor in human placenta,” Growth Factors, vol. 12, no. 3, pp. 235–243, 1995. View at Publisher · View at Google Scholar · View at Scopus
  35. D. E. Clark, S. K. Smith, A. M. Sharkey, and D. S. Charnock-Jones, “Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy,” Human Reproduction, vol. 11, no. 5, pp. 1090–1098, 1996. View at Publisher · View at Google Scholar · View at Scopus
  36. D. E. Clark, S. K. Smith, D. Licence, A. L. Evans, and D. S. Charnock-Jones, “Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation,” Journal of Endocrinology, vol. 159, no. 3, pp. 459–467, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Khaliq, X. F. Li, M. Shams et al., “Localisation of placenta growth factor (PIGF) in human term placenta,” Growth Factors, vol. 13, no. 3-4, pp. 243–250, 1996. View at Publisher · View at Google Scholar · View at Scopus
  38. M. G. Persico, V. Vincenti, and T. DiPalma, “Structure, Expression and Receptor-Binding Properties of Placenta Growth Factor (PlGF),” in Vascular Growth Factors and Angiogenesis, vol. 237 of Current Topics in Microbiology and Immunology, pp. 31–40, Springer Berlin Heidelberg, Berlin, Heidelberg, 1999. View at Publisher · View at Google Scholar
  39. G. Viglietto, D. Maglione, M. Rambaldi et al., “Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (P1GF) associated with malignancy in human thyroid tumors and cell lines,” Oncogene, vol. 11, no. 8, pp. 1569–1579, 1995. View at Google Scholar · View at Scopus
  40. G. Voros, E. Maquoi, D. Demeulemeester, N. Clerx, D. Collen, and H. R. Lijnen, “Modulation of angiogenesis during adipose tissue development in murine models of obesity,” Endocrinology, vol. 146, no. 10, pp. 4545–4554, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. C. De Vries, J. A. Escobedo, H. Ueno, K. Houck, N. Ferrara, and L. T. Williams, “The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor,” Science, vol. 255, no. 5047, pp. 989–991, 1992. View at Publisher · View at Google Scholar · View at Scopus
  42. B. I. Terman, M. Dougher-Vermazen, M. E. Carrion et al., “Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor,” Biochemical and Biophysical Research Communications, vol. 187, no. 3, pp. 1579–1586, 1992. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Shibuya, S. Yamaguchi, A. Yamane et al., “Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely relatd to the fms family,” Oncogene, vol. 5, no. 4, pp. 519–524, 1990. View at Google Scholar · View at Scopus
  44. B. I. Terman, M. E. Carrion, E. Kovacs, B. A. Rasmussen, R. L. Eddy, and T. B. Shows, “Identification of a new endothelial cell growth factor receptor tyrosine kinase,” Oncogene, vol. 6, no. 9, pp. 1677–1683, 1991. View at Google Scholar · View at Scopus
  45. R. L. Kendall and K. A. Thomas, “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 90, no. 22, pp. 10705–10709, 1993. View at Publisher · View at Google Scholar · View at Scopus
  46. R. J. Levine and S. A. Karumanchi, “Circulating angiogenic factors in preeclampsia,” Clinical Obstetrics and Gynecology, vol. 48, no. 2, pp. 372–386, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. S. E. Maynard, J. Y. Min, J. Merchan et al., “Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction hypertension, and proteinuria in preeclampsia,” The Journal of Clinical Investigation, vol. 111, no. 5, pp. 649–658, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. C. J. Robinson, D. D. Johnson, E. Y. Chang, D. M. Armstrong, and W. Wang, “Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia,” American Journal of Obstetrics & Gynecology, vol. 195, no. 1, pp. 255–259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. A. C. Staff, K. Braekke, N. K. Harsem, T. Lyberg, and M. R. Holthe, “Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 122, no. 1, pp. 33–39, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. V. Tsatsaris, F. Goffin, C. Munaut et al., “Overexpression of the Soluble Vascular Endothelial Growth Factor Receptor in Preeclamptic Patients: Pathophysiological Consequences,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 11, pp. 5555–5563, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. K.-A. Wathén, E. Tuutti, U.-H. Stenman et al., “Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 1, pp. 180–184, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. N. A. Bersinger and R. A. Ødegård, “Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies,” Acta Obstetricia et Gynecologica Scandinavica, vol. 83, no. 1, pp. 37–45, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. R. J. Levine, S. E. Maynard, C. Qian et al., “Circulating angiogenic factors and the risk of preeclampsia,” The New England Journal of Medicine, vol. 350, no. 7, pp. 672–683, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Chaiworapongsa, R. Romero, J. Espinoza et al., “Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: Young Investigator Award,” American Journal of Obstetrics & Gynecology, vol. 190, no. 6, pp. 1541–1550, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. J.-Y. Chung, Y. Song, Y. Wang, R. R. Magness, and J. Zheng, “Differential Expression of Vascular Endothelial Growth Factor (VEGF), Endocrine Gland Derived-VEGF, and VEGF Receptors in Human Placentas from Normal and Preeclamptic Pregnancies,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 5, pp. 2484–2490, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. A.-K. Wikström, A. Larsson, U. J. Eriksson, P. Nash, S. Nordén-Lindeberg, and M. Olovsson, “Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia,” Obstetrics & Gynecology, vol. 109, no. 6, pp. 1368–1374, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Chaiworapongsa, R. Romero, Y. M. Kim et al., “Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia,” The Journal of Maternal-Fetal and Neonatal Medicine, vol. 17, no. 1, pp. 3–18, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Romero, J. K. Nien, J. Espinoza et al., “A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 21, no. 1, pp. 9–23, 2009. View at Publisher · View at Google Scholar
  59. M. Simon, H.-J. Grone, O. Johren et al., “Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney,” American Journal of Physiology - Renal Fluid and Electrolyte Physiology, vol. 268, no. 2, pp. F240–F250, 1995. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Simon, W. Röckl, C. Hornig et al., “Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: Localization and [125I]VEGF binding sites,” Journal of the American Society of Nephrology, vol. 9, no. 6, pp. 1032–1044, 1998. View at Google Scholar · View at Scopus
  61. S. Rana, C. E. Powe, S. Salahuddin et al., “Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia,” Circulation, vol. 125, no. 7, pp. 911–919, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Thadhani, W. P. Mutter, M. Wolf et al., “First trimester placental growth factor and soluble fms -like tyrosine kinase 1 and risk for preeclampsia,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 2, pp. 770–775, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. B. M. Polliotti, A. G. Fry, D. N. Saller Jr., R. A. Mooney, C. Cox, and R. K. Miller, “Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia,” Obstetrics & Gynecology, vol. 101, no. 6, pp. 1266–1274, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. L. C. Y. Poon, N. A. Kametas, N. Maiz, R. Akolekar, and K. H. Nicolaides, “First-trimester prediction of hypertensive disorders in pregnancy,” Hypertension, vol. 53, no. 5, pp. 812–818, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. N. Su, C. N. Lee, W. F. Cheng, W. Y. Shau, S. N. Chow, and F. J. Hsieh, “Decreased maternal serum placenta growth factor in early second trimester and preeclampsia,” Obstetrics & Gynecology, vol. 97, no. 6, pp. 898–904, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. L. J. Vatten, A. Eskild, T. I. L. Nilsen, S. Jeansson, P. A. Jenum, and A. C. Staff, “Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia,” American Journal of Obstetrics & Gynecology, vol. 196, no. 3, pp. 239–e6, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. D. S. Torry, H.-S. Wang, T.-H. Wang, M. R. Caudle, and R. J. Torry, “Preeclampsia is associated with reduced serum levels of placenta growth factor,” American Journal of Obstetrics & Gynecology, vol. 179, no. 6 I, pp. 1539–1544, 1998. View at Publisher · View at Google Scholar · View at Scopus
  68. R. Akolekar, E. Zaragoza, L. C. Y. Poon, S. Pepes, and K. H. Nicolaides, “Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia,” Ultrasound in Obstetrics & Gynecology, vol. 32, pp. 732–773, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Krauss, H. Pauer, and H. G. Augustin, “Prospective analysis of placenta growth factor ( PlGF ) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia,” Hypertension in Pregnancy, vol. 23, no. 1, pp. 101–111, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. R. N. Taylor, J. Grimwood, R. S. Taylor, M. T. McMaster, S. J. Fisher, and R. A. North, “Longitudinal serum concentrations of placental growth factor: Evidence for abnormal placental angiogenesis in pathologic pregnancies,” American Journal of Obstetrics & Gynecology, vol. 188, no. 1, pp. 177–182, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. S. C. Tidwell, H. Ho, W. Chiu, R. J. Torry, and D. S. Torry, “Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia,” American Journal of Obstetrics & Gynecology, vol. 184, no. 6, pp. 1267–1272, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. M. L. Tjoa, J. M. G. van Vugt, M. A. M. Mulders, R. B. H. Schutgens, C. B. M. Oudejans, and I. J. van Wijk, “Plasma placenta growth factor levels in midtrimester pregnancies,” Obstetrics & Gynecology, vol. 98, no. 4, pp. 600–607, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. D. P. Holden, S. A. Fickling, G. S. Whitley, and S. S. Nussey, “Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia,” American Journal of Obstetrics & Gynecology, vol. 178, no. 3, pp. 551–556, 1998. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. J. Kim, H. S. Park, H. Y. Lee et al., “Reduced L-arginine level and decreased placental eNOS activity in preeclampsia,” Placenta, vol. 27, no. 4-5, pp. 438–444, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Laskowska and J. Oleszczuk, “Evaluation of ADMA levels in women with pregnancies complicated by severe preeclampsia,” Archives of Perinatal Medicine, vol. 17, no. 1, pp. 33–36, 2011. View at Google Scholar · View at Scopus
  76. R. Maas, R. H. Böger, E. Schwedhelm et al., “Plasma Concentrations of Asymmetric Dimethylarginine (ADMA) in Colombian Women with Pre-eclampsia [4],” Journal of the American Medical Association, vol. 291, no. 7, pp. 823-824, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Noorbakhsh, M. Kianpour, and M. Nematbakhsh, “Serum Levels of Asymmetric Dimethylarginine, Vascular Endothelial Growth Factor, and Nitric Oxide Metabolite Levels in Preeclampsia Patients,” ISRN Obstetrics and Gynecology, vol. 2013, pp. 1–5, 2013. View at Publisher · View at Google Scholar
  78. E. Gumus, M. A. Atalay, B. Cetinkaya Demir, and E. Sahin Gunes, “Possible role of asymmetric dimethylarginine (ADMA) in prediction of perinatal outcome in preeclampsia and fetal growth retardation related to preeclampsia,” The Journal of Maternal-Fetal and Neonatal Medicine, vol. 29, no. 23, pp. 3806–3811, 2016. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Maeda, T. Yoshimura, and H. Okamura, “Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, in maternal and fetal circulation,” J. Soc. Gynecol. Investig, vol. 10, p. 24, 2003. View at Google Scholar
  80. A. Pettersson, T. Hedner, and I. Milsom, “Increased circulating concentrations of asymmetric dimethyl arginine (ADMA, an endogenous inhibitor of nitric oxide synthesis, in preeclampsia,” Acta Obstet. Gynecol. Scand, vol. 77, pp. 808–813, 1998. View at Publisher · View at Google Scholar
  81. D. Rizos, M. Eleftheriades, E. Batakis et al., “Levels of asymmetric dimethylarginine throughout normal pregnancy and in pregnancies complicated with preeclampsia or had a small for gestational age baby,” The Journal of Maternal-Fetal and Neonatal Medicine, vol. 25, no. 8, pp. 1311–1315, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. P. D. Speer, R. W. Powers, M. P. Frank, G. Harger, N. Markovic, and J. M. Roberts, “Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants,” American Journal of Obstetrics & Gynecology, vol. 198, no. 1, pp. 112.e1–112.e7, 2008. View at Publisher · View at Google Scholar
  83. M. D. Savvidou, A. D. Hingorani, D. Tsikas, J. C. Frölich, P. Vallance, and K. H. Nicolaides, “Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia,” The Lancet, vol. 361, no. 9368, pp. 1511–1517, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. H. Tsukahara, N. Ohta, S. Tokuriki et al., “Determination of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, in umbilical blood,” Metabolism - Clinical and Experimental, vol. 57, no. 2, pp. 215–220, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Jeyabalan, S. McGonigal, C. Gilmour, C. A. Hubel, and A. Rajakumar, “Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia,” Placenta, vol. 29, no. 6, pp. 555–563, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. C. J. Robinson and D. D. Johnson, “Soluble endoglin as a second-trimester marker for preeclampsia,” American Journal of Obstetrics & Gynecology, vol. 197, no. 2, pp. 174.e1–174.e5, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. R. J. Levine, C. Lam, C. Qian et al., “Soluble endoglin and other circulating antiangiogenic factors in preeclampsia,” The New England Journal of Medicine, vol. 355, no. 10, pp. 992–1005, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Rana, S. A. Karumanchi, R. J. Levine et al., “Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia,” Hypertension, vol. 50, no. 1, pp. 137–142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. H. Stepan, T. Krämer, and R. Faber, “Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 7, pp. 2831–2834, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. H. Stepan, A. Geipel, F. Schwarz, T. Krämer, N. Wessel, and R. Faber, “Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion,” American Journal of Obstetrics & Gynecology, vol. 198, no. 2, pp. 175–e6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Venkatesha, M. Toporsian, C. Lam et al., “Erratum: Soluble endoglin contributes to the pathogenesis of preeclampsia (Nature Medicine (2006) 12, (642-649)),” Nature Medicine, vol. 12, no. 7, p. 862, 2006. View at Google Scholar · View at Scopus
  92. O. Burger, E. Pick, J. Zwickel et al., “Placental protein 13 (PP-13): Effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies,” Placenta, vol. 25, no. 7, pp. 608–622, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. B. Huppertz, M. Sammar, I. Chefetz, P. Neumaier-Wagner, C. Bartz, and H. Meiri, “Longitudinal determination of serum placental protein 13 during development of preeclampsia,” Fetal Diagnosis and Therapy, vol. 24, no. 3, pp. 230–236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. I. Chafetz, I. Kuhnreich, M. Sammar et al., “First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction,” American Journal of Obstetrics & Gynecology, vol. 197, no. 1, pp. 35.e1–35.e7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Khalil, N. J. Cowans, K. Spencer, S. Goichman, H. Meiri, and K. Harrington, “First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk,” Prenatal Diagnosis, vol. 29, no. 8, pp. 781–789, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. K. H. Nicolaides, R. Bindra, O. M. Turan et al., “A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound,” Ultrasound in Obstetrics & Gynecology, vol. 27, no. 1, pp. 13–17, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. K. Spencer, N. J. Cowans, I. Chefetz, J. Tal, I. Kuhnreich, and H. Meiri, “Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia,” Prenatal Diagnosis, vol. 27, no. 3, pp. 258–263, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. K. Spencer, N. J. Cowans, I. Chefetz, J. Tal, and H. Meiri, “First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia,” Ultrasound in Obstetrics & Gynecology, vol. 29, no. 2, pp. 128–134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. R. Romero, J. P. Kusanovic, N. G. Than et al., “First-trimester maternal serum PP13 in the risk assessment for preeclampsia,” American Journal of Obstetrics & Gynecology, vol. 199, no. 2, pp. 122–e11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. H. Aksoy, Y. Kumtepe, F. Akçay, and A. K. Yildirim, “Correlation of P-selectin and lipoprotein(a), and other lipid parameters in preeclampsia,” Clinical and Experimental Medicine, vol. 2, no. 1, pp. 39–43, 2002. View at Publisher · View at Google Scholar · View at Scopus
  101. I. Banzola, A. Farina, M. Concu et al., “Performance of a panel of maternal serum markers in predicting preeclampsia at 11-15 weeks' gestation,” Prenatal Diagnosis, vol. 27, no. 11, pp. 1005–1010, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. F. Bretelle, F. Sabatier, D. Desprez et al., “Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction,” Thrombosis and Haemostasis, vol. 89, no. 3, pp. 486–492, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. A. Halim, N. Kanayama, E. El Maradny et al., “Plasma P selectin (GMP-140) and glycocalicin are elevated in preeclampsia and eclampsia: Their significances,” American Journal of Obstetrics & Gynecology, vol. 174, no. 1, pp. 272–277, 1996. View at Publisher · View at Google Scholar · View at Scopus
  104. W. Heyl, S. Handt, F. Reister et al., “Elevated soluble adhesion molecules in women with pre-eclampsia,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 86, no. 1, pp. 35–41, 1999. View at Publisher · View at Google Scholar
  105. C. A. R. Lok, R. Nieuwland, A. Sturk et al., “Microparticle-associated P-selectin reflects platelet activation in preeclampsia,” Platelets, vol. 18, no. 1, pp. 68–72, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. T. Chaiworapongsa, R. Romero, J. Yoshimatsu et al., “Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 12, no. 1, pp. 19–27, 2009. View at Publisher · View at Google Scholar
  107. P. Bosio, S. Cannon, P. McKenna, C. O'Herlihy, R. Conroy, and H. Brady, “Plasma P-selectin is elevated in the first trimester in women who subsequently develop pre-eclampsia,” BJOG: An International Journal of Obstetrics & Gynaecology, vol. 108, no. 7, pp. 709–715, 2001. View at Publisher · View at Google Scholar
  108. M. E. Chavarría, L. Lara-González, Y. García-Paleta, V. S. Vital-Reyes, and A. Reyes, “Adhesion molecules changes at 20 gestation weeks in pregnancies complicated by preeclampsia,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 137, no. 2, pp. 157–164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. A. A. Senna, M. Zedan, G. E. Abd El Salam, and A. I. El Mashad, “Study of plasma adrenomedullin level in normal pregnancy and preclampsia,” The Medscape Journal of Medicine, vol. 10, no. 2, article no. 29, 2008. View at Google Scholar · View at Scopus
  110. J. Laigaard, T. Sørensen, S. Placing et al., “Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia,” Obstetrics & Gynecology, vol. 106, no. 1, pp. 144–149, 2005. View at Publisher · View at Google Scholar · View at Scopus
  111. K. H. Nicolaides, L. C. Y. Poon, T. Chelemen, O. Granvillano, and I. Pandeva, “First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome,” Obstetrics & Gynecology, vol. 112, no. 5, pp. 1082–1090, 2008. View at Publisher · View at Google Scholar · View at Scopus
  112. K. Spencer, N. J. Cowans, and A. Stamatopoulou, “ADAM12s in maternal serum as a potential marker of pre-eclampsia,” Prenatal Diagnosis, vol. 28, no. 3, pp. 212–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  113. I. Cetin, V. Cozzi, F. Pasqualini et al., “Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction,” American Journal of Obstetrics & Gynecology, vol. 194, no. 5, pp. 1347–1353, 2006. View at Publisher · View at Google Scholar · View at Scopus
  114. P. Rovere-Querini, S. Antonacci, G. Dell'Antonio et al., “Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia,” Obstetrics & Gynecology, vol. 108, no. 1, pp. 148–155, 2006. View at Publisher · View at Google Scholar · View at Scopus
  115. N. J. Cowans and K. Spencer, “First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system,” Prenatal Diagnosis, vol. 27, no. 3, pp. 264–271, 2007. View at Publisher · View at Google Scholar · View at Scopus
  116. C. Y. T. Ong, A. W. Liao, K. Spencer, S. Munim, and K. H. Nicolaides, “First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein a as predictors of pregnancy complications,” British Journal of Obstetrics and Gynaecology, vol. 107, no. 10, pp. 1265–1270, 2000. View at Publisher · View at Google Scholar · View at Scopus
  117. K. Spencer, N. J. Cowans, and K. H. Nicolaides, “Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia,” Prenatal Diagnosis, vol. 28, no. 1, pp. 7–10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. Y. Yaron, S. Heifetz, Y. Ochshorn, O. Lehavi, and A. Orr-Urtreger, “Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome,” Prenatal Diagnosis, vol. 22, no. 9, pp. 778–782, 2002. View at Publisher · View at Google Scholar · View at Scopus
  119. L. Dugoff, J. C. Hobbins, F. D. Malone et al., “First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial),” American Journal of Obstetrics & Gynecology, vol. 191, no. 4, pp. 1446–1451, 2004. View at Publisher · View at Google Scholar · View at Scopus
  120. D. Krantz, L. Goetzl, J. L. Simpson et al., “Association of extreme first-trimester free human chorionic gonadotropin-β, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes,” American Journal of Obstetrics & Gynecology, vol. 191, no. 4, pp. 1452–1458, 2004. View at Publisher · View at Google Scholar · View at Scopus
  121. K. Spencer, N. J. Cowans, F. Molina, K. O. Kagan, and K. H. Nicolaides, “First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery,” Ultrasound in Obstetrics & Gynecology, vol. 31, no. 2, pp. 147–152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. N. Tul, S. Pusenjak, J. Osredkar, K. Spencer, and Z Novak-Antolic, “Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A,” Prenatal Diagnosis, vol. 23, no. 12, pp. 990–996, 2003. View at Publisher · View at Google Scholar
  123. G. C. Smith, E. J. Stenhouse, J. A. Crossley, D. A. Aitken, A. D. Cameron, and J. M. Connor, “Early Pregnancy Levels of Pregnancy-Associated Plasma Protein A and the Risk of Intrauterine Growth Restriction, Premature Birth, Preeclampsia, and Stillbirth,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 4, pp. 1762–1767, 2002. View at Publisher · View at Google Scholar
  124. W. Hu, Z. Wang, H. Wang, H. Huang, and M. Dong, “Serum visfatin levels in late pregnancy and pre-eclampsia,” Acta Obstetricia et Gynecologica Scandinavica, vol. 87, no. 4, pp. 413–418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. A. Farina, A. Sekizawa, M. Iwasaki, R. Matsuoka, K. Ichizuka, and T. Okai, “Total cell-free DNA (β-globin gene) distribution in maternal plasma at the second trimester: A new prospective for preeclampsia screening,” Prenatal Diagnosis, vol. 24, no. 9, pp. 722–726, 2004. View at Publisher · View at Google Scholar · View at Scopus
  126. A. Sekizawa, A. Farina, K. Koide et al., “β-globin DNA in maternal plasma as a molecular marker of pre-eclampsia,” Prenatal Diagnosis, vol. 24, no. 9, pp. 697–700, 2004. View at Publisher · View at Google Scholar
  127. D. W. Swinkels, J. B. De Kok, J. C. M. Hendriks, E. Wiegerinck, P. L. M. Zusterzeel, and E. A. P. Steegers, “Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome as a complication of preeclampsia in pregnant women increases the amount of cell-free fetal and maternal DNA in maternal plasma and serum,” Clinical Chemistry, vol. 48, no. 4, pp. 650–653, 2002. View at Google Scholar · View at Scopus
  128. Y. M. D. Lo, M. S. C. Tein, T. K. Lau et al., “Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis,” American Journal of Human Genetics, vol. 62, no. 4, pp. 768–775, 1998. View at Publisher · View at Google Scholar · View at Scopus
  129. X. Y. Zhong, H. Laivuori, J. C. Livingston et al., “Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia,” American Journal of Obstetrics & Gynecology, vol. 184, no. 3, pp. 414–419, 2001. View at Publisher · View at Google Scholar · View at Scopus
  130. R. J. Levine, C. Qian, E. S. Leshane et al., “Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia,” American Journal of Obstetrics & Gynecology, vol. 190, no. 3, pp. 707–713, 2004. View at Publisher · View at Google Scholar · View at Scopus
  131. R. M. Silver, L. Myatt, J. C. Hauth et al., “Cell-Free Total and Fetal DNA in First Trimester Maternal Serum and Subsequent Development of Preeclampsia,” American Journal of Perinatology, vol. 34, no. 2, pp. 191–198, 2017. View at Publisher · View at Google Scholar · View at Scopus
  132. X. Y. Zhong, W. Holzgreve, and S. Hahn, “The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia,” Hypertension in Pregnancy, vol. 21, no. 1, pp. 77–83, 2002. View at Publisher · View at Google Scholar · View at Scopus
  133. N. Leung Tse, Jun. Zhang, K. Tze, Y. S. Lisa, and Y. M. Dennis Lo, Increased Maternal Plasma Fetal DNA Concentrations in Women Who Eventually Develop Preeclampsia. Clinical Chemistry, vol. 47, ‘Increased Maternal Plasma Fetal DNA Concentrations in Women Who Eventually Develop Preeclampsia.’ Clinical Chemistry 47 (1, 137–39, 2001.
  134. S. De Falco, “The discovery of placenta growth factor and its biological activity,” Experimental & Molecular Medicine, vol. 44, no. 1, p. 1, 2012. View at Publisher · View at Google Scholar
  135. P. Vuorela, E. Hatva, A. Lymboussaki et al., “Expression of vascular endothelial growth factor and placenta growth factor in human placenta,” Biology of Reproduction, vol. 56, no. 2, pp. 489–494, 1997. View at Publisher · View at Google Scholar · View at Scopus
  136. J. Dommisse and A. J. Tiltman, “Placental bed biopsies in placental abruption,” An International Journal of Obstetrics & Gynaecology, vol. 99, no. 8, pp. 651–654, 1992. View at Publisher · View at Google Scholar · View at Scopus
  137. T. K. Eskes, “Abruptio placentae,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 75, no. 1, pp. 63–70, 1997. View at Publisher · View at Google Scholar
  138. R. Thadhani, J. L. Ecker, W. P. Mutter et al., “Insulin Resistance and Alterations in Angiogenesis: Additive Insults That May Lead to Preeclampsia,” Hypertension, vol. 43, no. 5, pp. 988–992, 2004. View at Publisher · View at Google Scholar · View at Scopus
  139. H. Stepan, A. Unversucht, N. Wessel, and R. Faber, “Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion,” Hypertension, vol. 49, no. 4, pp. 818–824, 2007. View at Publisher · View at Google Scholar · View at Scopus
  140. C. S. Buhimschi, E. R. Norwitz, E. Funai et al., “Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia,” American Journal of Obstetrics & Gynecology, vol. 192, no. 3, pp. 734–741, 2005. View at Publisher · View at Google Scholar · View at Scopus
  141. A. C. Staff, K. Braekke, G. M. Johnsen, S. A. Karumanchi, and N. K. Harsem, “Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia,” American Journal of Obstetrics & Gynecology, vol. 197, no. 2, pp. 176–e6, 2007. View at Publisher · View at Google Scholar · View at Scopus
  142. B. C. Smith and J. M. Denu, “Chemical mechanisms of histone lysine and arginine modifications,” Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, vol. 1789, no. 1, pp. 45–57, 2009. View at Publisher · View at Google Scholar
  143. A. Scoumanne and X. Chen, “Protein methylation: A new mechanism of p53 tumor suppressor regulation,” Histology and Histopathology, vol. 23, no. 9, pp. 1143–1149, 2008. View at Google Scholar · View at Scopus
  144. M. T. Bedford and S. Richard, “Arginine methylation: an emerging regulator of protein function,” Molecular Cell, vol. 18, no. 3, pp. 263–272, 2005. View at Publisher · View at Google Scholar · View at Scopus
  145. L. Sibal, S. C. Agarwal, P. D. Home, and R. H. Boger, “The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease,” Current Cardiology Reviews, vol. 6, no. 2, pp. 82–90, 2010. View at Publisher · View at Google Scholar · View at Scopus
  146. S. G. Clarke, “Protein methylation at the surface and buried deep: Thinking outside the histone box,” Trends in Biochemical Sciences, vol. 38, no. 5, pp. 243–252, 2013. View at Publisher · View at Google Scholar · View at Scopus
  147. T. Ogawa, M. Kimoto, and K. Sasaoka, “Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats,” Biochemical and Biophysical Research Communications, vol. 148, no. 2, pp. 671–677, 1987. View at Publisher · View at Google Scholar · View at Scopus
  148. A. Ito, P. S. Tsao, S. Adimoolam, M. Kimoto, T. Ogawa, and J. P. Cooke, “Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase,” Circulation, vol. 99, no. 24, pp. 3092–3095, 1999. View at Publisher · View at Google Scholar · View at Scopus
  149. P. Vallance, A. Leone, A. Calver, J. Collier, and S. Moncada, “Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure,” The Lancet, vol. 339, no. 8793, pp. 572–575, 1992. View at Publisher · View at Google Scholar · View at Scopus
  150. M. S. Goligorsky, “Endothelial cell dysfunction: can’t live with it, how to live without it,” American Journal of Physiology-Renal Physiology, vol. 288, no. 5, pp. F871–F880, 2005. View at Publisher · View at Google Scholar
  151. J. P. Cooke, E. Rossitch Jr., N. A. Andon, J. Loscalzo, and V. J. Dzau, “Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator,” The Journal of Clinical Investigation, vol. 88, no. 5, pp. 1663–1671, 1991. View at Publisher · View at Google Scholar · View at Scopus
  152. R. F. Furchgott and J. V. Zawadzki, “The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine,” Nature, vol. 288, no. 5789, pp. 373–376, 1980. View at Publisher · View at Google Scholar · View at Scopus
  153. A. Wolf, C. Zalpour, G. Theilmeier et al., “Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans,” Journal of the American College of Cardiology, vol. 29, no. 3, pp. 479–485, 1997. View at Publisher · View at Google Scholar · View at Scopus
  154. P. Kubes, M. Suzuki, and D. N. Granger, “Nitric oxide: an endogenous modulator of leukocyte adhesion,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 88, no. 11, pp. 4651–4655, 1991. View at Publisher · View at Google Scholar · View at Scopus
  155. R. H. Böger, “Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor,” Journal of Nutrition, vol. 134, no. 10, pp. 2842S–2847S, 2004. View at Publisher · View at Google Scholar
  156. R. J. MacAllister, H. Parry, M. Kimoto et al., “Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase,” British Journal of Pharmacology, vol. 119, no. 8, pp. 1533–1540, 1996. View at Publisher · View at Google Scholar · View at Scopus
  157. M. C. Stühlinger, R. K. Oka, E. E. Graf et al., “Endothelial Dysfunction Induced by Hyperhomocyst(e)inemia: Role of Asymmetric Dimethylarginine,” Circulation, vol. 108, pp. 933–938, 2003. View at Google Scholar
  158. K. Y. Lin, A. Ito, T. Asagami et al., “Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase,” Circulation, vol. 106, no. 8, pp. 987–992, 2002. View at Publisher · View at Google Scholar · View at Scopus
  159. M. Weis, T. N. Kledal, K. Y. Lin et al., “Cytomegalovirus Infection Impairs the Nitric Oxide Synthase Pathway: Role of Asymmetric Dimethylarginine in Transplant Arteriosclerosis,” Circulation, vol. 109, no. 4, pp. 500–505, 2004. View at Publisher · View at Google Scholar · View at Scopus
  160. M. C. Stühlinger, P. S. Tsao, J.-H. Her, M. Kimoto, R. F. Balint, and J. P. Cooke, “Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine,” Circulation, vol. 104, no. 21, pp. 2569–2575, 2001. View at Publisher · View at Google Scholar · View at Scopus
  161. J.-F. Couture, L. M. A. Dirk, J. S. Brunzelle, R. L. Houtz, and R. C. Trievel, “Structural origins for the product specificity of SET domain protein methyltransferases,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 105, no. 52, pp. 20659–20664, 2008. View at Publisher · View at Google Scholar · View at Scopus
  162. X. Zhang and T. C. Bruice, “Enzymatic mechanism and product specificity of SET-domain protein lysine methyltransferases,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 105, no. 15, pp. 5728–5732, 2008. View at Publisher · View at Google Scholar · View at Scopus
  163. M. T. Bedford and S. G. Clarke, “Protein arginine methylation in mammals: who, what, and why,” Molecular Cell, vol. 33, no. 1, pp. 1–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  164. Y. Yang and M. T. Bedford, “Protein arginine methyltransferases and cancer,” Nature Reviews Cancer, vol. 13, no. 1, pp. 37–50, 2013. View at Publisher · View at Google Scholar · View at Scopus
  165. C. I. Zurita-Lopez, T. Sandberg, R. Kelly, and S. G. Clarke, “Human protein arginine methyltransferase 7 (PRMT7) is a type III enzyme forming ω-NG-monomethylated arginine residues,” The Journal of Biological Chemistry, vol. 287, no. 11, pp. 7859–7870, 2012. View at Publisher · View at Google Scholar · View at Scopus
  166. H. L. Schubert, R. M. Blumenthal, and X. Cheng, “Many paths to methyltransfer: A chronicle of convergence,” Trends in Biochemical Sciences, vol. 28, no. 6, pp. 329–335, 2003. View at Publisher · View at Google Scholar · View at Scopus
  167. P. A. del Rizzo and R. C. Trievel, “Substrate and product specificities of SET domain methyltransferases,” Epigenetics, vol. 6, no. 9, pp. 1059–1067, 2011. View at Publisher · View at Google Scholar · View at Scopus
  168. K. L. Tkaczuk, S. Dunin-Horkawicz, E. Purta, and J. M. Bujnicki, “Structural and evolutionary bioinformatics of the SPOUT superfamily of methyltransferases,” BMC Bioinformatics, vol. 8, article 73, 2007. View at Publisher · View at Google Scholar · View at Scopus
  169. Q. Feng, H. Wang, H. H. Ng et al., “Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain,” Current Biology, vol. 12, no. 12, pp. 1052–1058, 2002. View at Publisher · View at Google Scholar · View at Scopus
  170. C. Qian and M.-M. Zhou, “SET domain protein lysine methyltransferases: structure, specificity and catalysis,” Cellular and Molecular Life Sciences, vol. 63, no. 23, pp. 2755–2763, 2006. View at Publisher · View at Google Scholar · View at Scopus
  171. T. C. Petrossian and S. G. Clarke, “Uncovering the human methyltransferasome,” Molecular & Cellular Proteomics, vol. 10, no. 1, 2011. View at Publisher · View at Google Scholar · View at Scopus
  172. V. M. Richon, D. Johnston, C. J. Sneeringer et al., “Chemogenetic Analysis of Human Protein Methyltransferases,” Chemical Biology & Drug Design, vol. 78, no. 2, pp. 199–210, 2011. View at Publisher · View at Google Scholar · View at Scopus
  173. S. Kernstock, E. Davydova, M. Jakobsson et al., “Lysine methylation of VCP by a member of a novel human protein methyltransferase family,” Nature Communications, vol. 3, article no. 1038, 2012. View at Publisher · View at Google Scholar · View at Scopus
  174. R. Magnani, L. M. A. Dirk, R. C. Trievel, and R. L. Houtz, “Calmodulin methyltransferase is an evolutionarily conserved enzyme that trimethylates Lys-115 in calmodulin,” Nature Communications, vol. 1, no. 4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  175. A. T. Nguyen and Y. Zhang, “The diverse functions of Dot1 and H3K79 methylationanh,” Genes & Development, vol. 25, no. 13, pp. 1345–1358, 2011. View at Publisher · View at Google Scholar · View at Scopus
  176. K. J. Webb, Q. Al-Hadid, C. I. Zurita-Lopez, B. D. Young, R. S. Lipson, and S. G. Clarke, “The ribosomal L1 protuberance in yeast is methylated on a lysine residue catalyzed by a seven-β-strand methyltransferase,” The Journal of Biological Chemistry, vol. 286, no. 21, pp. 18405–18413, 2011. View at Publisher · View at Google Scholar · View at Scopus
  177. S. C. Dillon, X. Zhang, R. C. Trievel, and X. Cheng, “The SET-domain protein superfamily: Protein lysine methyltransferases,” Genome Biology, vol. 6, no. 8, article no. 227, 2005. View at Publisher · View at Google Scholar · View at Scopus
  178. T. Shimazu, J. Barjau, Y. Sohtome, M. Sodeoka, and Y. Shinkai, “Selenium-based S-adenosylmethionine analog reveals the mammalian seven-beta-strand methyltransferase METTL10 to be an EF1A1 lysine methyltransferase,” PLoS ONE, vol. 9, no. 8, Article ID e105394, 2014. View at Publisher · View at Google Scholar · View at Scopus
  179. P. Cloutier, M. Lavallée-Adam, D. Faubert, M. Blanchette, and B. Coulombe, “A Newly Uncovered Group of Distantly Related Lysine Methyltransferases Preferentially Interact with Molecular Chaperones to Regulate Their Activity,” PLoS Genetics, vol. 9, no. 1, Article ID e1003210, 2013. View at Publisher · View at Google Scholar · View at Scopus
  180. J. C. Black, C. Van Rechem, and J. R. Whetstine, “Histone lysine methylation dynamics: establishment, regulation, and biological impact,” Molecular Cell, vol. 48, no. 4, pp. 491–507, 2012. View at Publisher · View at Google Scholar · View at Scopus
  181. J. C. Eissenberg and A. Shilatifard, “Histone H3 lysine 4 (H3K4) methylation in development and differentiation,” Developmental Biology, vol. 339, no. 2, pp. 240–249, 2010. View at Publisher · View at Google Scholar · View at Scopus
  182. R. A. Greenberg, “Histone tails: Directing the chromatin response to DNA damage,” FEBS Letters, vol. 585, no. 18, pp. 2883–2890, 2011. View at Publisher · View at Google Scholar · View at Scopus
  183. T. Kouzarides, “Chromatin modifications and their function,” Cell, vol. 128, no. 4, pp. 693–705, 2007. View at Publisher · View at Google Scholar · View at Scopus
  184. A. Nottke, M. P. Colaiácovo, and Y. Shi, “Developmental roles of the histone lysine demethylases,” Development, vol. 136, no. 6, pp. 879–889, 2009. View at Publisher · View at Google Scholar · View at Scopus
  185. M. T. Pedersen and K. Helin, “Histone demethylases in development and disease,” Trends in Cell Biology, vol. 20, no. 11, pp. 662–671, 2010. View at Publisher · View at Google Scholar · View at Scopus
  186. J. C. Black and J. R. Whetstine, “Tipping the lysine methylation balance in disease,” Biopolymers, vol. 99, no. 2, pp. 127–135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  187. E. L. Greer and Y. Shi, “Histone methylation: a dynamic mark in health, disease and inheritance,” Nature Reviews Genetics, vol. 13, no. 5, pp. 343–357, 2012. View at Publisher · View at Google Scholar · View at Scopus
  188. R. A. Copeland, M. P. Moyer, and V. M. Richon, “Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics,” Oncogene, vol. 32, no. 8, pp. 939–946, 2013. View at Publisher · View at Google Scholar · View at Scopus
  189. S. Hake, A. Xiao, and C. Allis, “Linking the epigenetic ‘language’ of covalent histone modifications to cancer,” British Journal of Cancer, vol. 90, no. 4, pp. 761–769, 2004. View at Publisher · View at Google Scholar
  190. H. Ü. Kaniskan and J. Jin, “Chemical probes of histone lysine methyltransferases,” ACS Chemical Biology, vol. 10, no. 1, pp. 40–50, 2015. View at Publisher · View at Google Scholar · View at Scopus
  191. R. A. Varier and H. T. M. Timmers, “Histone lysine methylation and demethylation pathways in cancer,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1815, no. 1, pp. 75–89, 2011. View at Publisher · View at Google Scholar · View at Scopus
  192. E. A. Pollina and A. Brunet, “Epigenetic regulation of aging stem cells,” Oncogene, vol. 30, no. 28, pp. 3105–3126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  193. M. Albert and K. Helin, “Histone methyltransferases in cancer,” Seminars in Cell & Developmental Biology, vol. 21, no. 2, pp. 209–220, 2010. View at Publisher · View at Google Scholar
  194. P. Chi, C. D. Allis, and G. G. Wang, “Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers,” Nature Reviews Cancer, vol. 10, no. 7, pp. 457–469, 2010. View at Publisher · View at Google Scholar · View at Scopus
  195. S. Varambally, S. M. Dhanasekaran, M. Zhou et al., “The polycomb group protein EZH2 is involved in progression of prostate cancer,” Nature, vol. 419, no. 6907, pp. 624–629, 2002. View at Publisher · View at Google Scholar · View at Scopus
  196. C. G. Kleer, Q. Cao, S. Varambally et al., “EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 100, no. 20, pp. 11606–11611, 2003. View at Publisher · View at Google Scholar · View at Scopus
  197. H. P. J. Visser, M. J. Gunster, H. C. Kluin-Nelemans et al., “The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma,” British Journal of Haematology, vol. 112, no. 4, pp. 950–958, 2001. View at Publisher · View at Google Scholar · View at Scopus
  198. R. Chen, Y. Tan, M. Wang et al., “Development of glycoprotein capture-based label-free method for the high-throughput screening of differential glycoproteins in hepatocellular carcinoma,” Molecular ##hssm###38; Cellular Proteomics, vol. 10, no. 7, Article ID M110.006445, 2011. View at Publisher · View at Google Scholar · View at Scopus
  199. R. Hamamoto, V. Saloura, and Y. Nakamura, “Critical roles of non-histone protein lysine methylation in human tumorigenesis,” Nature Reviews Cancer, vol. 15, no. 2, pp. 110–124, 2015. View at Publisher · View at Google Scholar · View at Scopus
  200. S. Ko, J. Ahn, C. S. Song, S. Kim, K. Knapczyk-Stwora, and B. Chatterjee, “Lysine methylation and functional modulation of androgen receptor by set9 methyltransferase,” Molecular Endocrinology, vol. 25, no. 3, pp. 433–444, 2011. View at Publisher · View at Google Scholar · View at Scopus
  201. S. C. Smith, P. N. Baker, and E. M. Symonds, “Placental apoptosis in normal human pregnancy,” American Journal of Obstetrics & Gynecology, vol. 177, no. 1, pp. 57–65, 1997. View at Publisher · View at Google Scholar · View at Scopus
  202. A. D. Allaire, K. A. Ballenger, S. R. Wells, M. J. McMahon, and B. A. Lessey, “Placental apoptosis in preeclampsia,” Obstetrics & Gynecology, vol. 96, no. 2, pp. 271–276, 2000. View at Publisher · View at Google Scholar · View at Scopus
  203. A. E. P. Heazell, H. R. Buttle, P. N. Baker, and I. P. Crocker, “Altered expression of regulators of caspase activity within trophoblast of normal pregnancies and pregnancies complicated by preeclampsia,” Reproductive Sciences, vol. 15, no. 10, pp. 1034–1043, 2008. View at Publisher · View at Google Scholar · View at Scopus
  204. D. N. Leung, S. C. Smith, K. To, D. S. Sahota, and P. N. Baker, “Increased placental apoptosis in pregnancies complicated by preeclampsia,” American Journal of Obstetrics & Gynecology, vol. 184, no. 6, pp. 1249-1250, 2001. View at Publisher · View at Google Scholar
  205. B. Huppertz and J. C. P. Kingdom, “Apoptosis in the trophoblast—role of apoptosis in placental morphogenesis,” Journal of the Society for Gynecologic Investigation, vol. 11, no. 6, pp. 353–362, 2004. View at Publisher · View at Google Scholar · View at Scopus
  206. A. N. Sharp, A. E. Heazell, I. P. Crocker, and G. Mor, “Placental Apoptosis in Health and Disease,” American Journal of Reproductive Immunology, vol. 64, no. 3, pp. 159–169, 2010. View at Publisher · View at Google Scholar
  207. A. N. Sharp, A. E. P. Heazell, D. Baczyk et al., “Preeclampsia is associated with alterations in the p53-pathway in villous trophoblast,” PLoS ONE, vol. 9, no. 1, Article ID e87621, 2014. View at Publisher · View at Google Scholar · View at Scopus
  208. T. Hung, S. Chen, L. Lo et al., “Increased Autophagy in Placentas of Intrauterine Growth-Restricted Pregnancies,” PLoS ONE, vol. 7, no. 7, p. e40957, 2012. View at Publisher · View at Google Scholar
  209. R. Levy, S. D. Smith, K. Yusuf et al., “Trophoblast apoptosis from pregnancies complicated by fetal growth restriction is associated with enhanced p53 expression,” American Journal of Obstetrics & Gynecology, vol. 186, no. 5, pp. 1056–1061, 2002. View at Publisher · View at Google Scholar · View at Scopus
  210. S. Chuikov, J. K. Kurash, J. R. Wilson et al., “Regulation of p53 activity through lysine methylation,” Nature, vol. 432, no. 7015, pp. 353–360, 2004. View at Publisher · View at Google Scholar · View at Scopus
  211. J. Oyake, M. Otaka, T. Matsuhashi et al., “Over-expression of 70-kDa heat shock protein confers protection against monochloramine-induced gastric mucosal cell injury,” Life Sciences, vol. 79, no. 3, pp. 300–305, 2006. View at Publisher · View at Google Scholar · View at Scopus
  212. S. Jirecek, M. Hohlagschwandtner, C. Tempfer, M. Knöfler, P. Husslein, and H. Zeisler, “Serum levels of heat shock protein 70 in patients with preeclampsia: A pilot-study,” Wiener Klinische Wochenschrift, vol. 114, no. 15-16, pp. 730–732, 2002. View at Google Scholar · View at Scopus
  213. J. Hageman, M. A. W. H. van Waarde, A. Zylicz, D. Walerych, and H. H. Kampinga, “The diverse members of the mammalian HSP70 machine show distinct chaperone-like activities,” Biochemical Journal, vol. 435, no. 1, pp. 127–142, 2011. View at Publisher · View at Google Scholar · View at Scopus
  214. E. L. Davies, M. M. F. V. G. Bacelar, M. J. Marshall et al., “Heat shock proteins form part of a danger signal cascade in response to lipopolysaccharide and GroEL,” Clinical & Experimental Immunology, vol. 145, no. 1, pp. 183–189, 2006. View at Publisher · View at Google Scholar · View at Scopus
  215. X. Luo, X. Zuo, B. Zhang et al., “Release of heat shock protein 70 and the effects of extracellular heat shock protein 70 on the production of IL-10 in fibroblast-like synoviocytes,” Cell Stress and Chaperones, vol. 13, no. 3, pp. 365–373, 2008. View at Publisher · View at Google Scholar · View at Scopus
  216. D. G. Millar, K. M. Garza, B. Odermatt et al., “Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo,” Nature Medicine, vol. 9, no. 12, pp. 1469–1476, 2003. View at Publisher · View at Google Scholar · View at Scopus
  217. H. H. Kampinga, J. Hageman, M. J. Vos et al., “Guidelines for the nomenclature of the human heat shock proteins,” Cell Stress and Chaperones, vol. 14, no. 1, pp. 105–111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  218. H. H. Kampinga and E. A. Craig, “The HSP70 chaperone machinery: J proteins as drivers of functional specificity,” Nature Reviews Molecular Cell Biology, vol. 11, no. 8, pp. 579–592, 2010. View at Publisher · View at Google Scholar · View at Scopus
  219. A. Fukushima, H. Kawahara, and C. Isurugi, “Changes in serum levels of heat shock protein 70 in preterm delivery and pre-eclampsia,” Journal of Obstetrics and Gynaecology Research, vol. 31, no. 1, pp. 72–77, 2005. View at Publisher · View at Google Scholar · View at Scopus
  220. J. K. Park, T. G. Kang, M. Y. Kang et al., “Increased NFAT5 expression stimulates transcription of Hsp70 in preeclamptic placentas,” Placenta, vol. 35, no. 2, pp. 109–116, 2014. View at Publisher · View at Google Scholar · View at Scopus
  221. F. Barut, A. Barut, B. Dogan Gun et al., “Expression of heat shock protein 70 and endothelial nitric oxide synthase in placental tissue of preeclamptic and intrauterine growth-restricted pregnancies,” Pathology - Research and Practice, vol. 206, no. 9, pp. 651–656, 2010. View at Publisher · View at Google Scholar · View at Scopus
  222. Y. Liu, N. Li, L. You, X. Liu, H. Li, and X. Wang, “HSP70 is associated with endothelial activation in placental vascular diseases,” Molecular Medicine, vol. 14, no. 9-10, pp. 561–566, 2008. View at Publisher · View at Google Scholar · View at Scopus
  223. H.-S. Cho, T. Shimazu, G. Toyokawa et al., “Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B,” Nature Communications, vol. 3, article 1072, 2012. View at Publisher · View at Google Scholar · View at Scopus
  224. A. Sawano, T. Takahashi, S. Yamaguchi, M. Aonuma, and M. Shibuya, “Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor,” Cell Growth & Differentiation, vol. 7, no. 2, pp. 213–221, 1996. View at Google Scholar · View at Scopus
  225. N. Ferrara and R. S. Kerbel, “Angiogenesis as a therapeutic target,” Nature, vol. 438, no. 7070, pp. 967–974, 2005. View at Publisher · View at Google Scholar · View at Scopus
  226. N. Rahimi, “Vascular endothelial growth factor receptors: Molecular mechanisms of activation and therapeutic potentials,” Experimental Eye Research, vol. 83, no. 5, pp. 1005–1016, 2006. View at Publisher · View at Google Scholar · View at Scopus
  227. D. Hanahan and J. Folkman, “Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis,” Cell, vol. 86, no. 3, pp. 353–364, 1996. View at Publisher · View at Google Scholar · View at Scopus
  228. W. Risau, “Mechanisms of angiogenesis,” Nature, vol. 386, no. 6626, pp. 671–674, 1997. View at Publisher · View at Google Scholar · View at Scopus
  229. G.-H. Fong, J. Rossant, M. Gertsenstein, and M. L. Breitman, “Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium,” Nature, vol. 376, no. 6535, pp. 66–70, 1995. View at Publisher · View at Google Scholar · View at Scopus
  230. S. Helske, P. Vuorela, O. Carpén, C. Hornig, H. Weich, and E. Halmesmäki, “Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies,” Molecular Human Reproduction, vol. 7, no. 2, pp. 205–210, 2001. View at Publisher · View at Google Scholar · View at Scopus
  231. Y. Zhou, M. McMaster, K. Woo et al., “Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome,” The American Journal of Pathology, vol. 160, no. 4, Article ID 62567, pp. 1405–1423, 2002. View at Publisher · View at Google Scholar · View at Scopus
  232. M. Kunizaki, R. Hamamoto, F. P. Silva et al., “The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3,” Cancer Research, vol. 67, no. 22, pp. 10759–10765, 2007. View at Publisher · View at Google Scholar · View at Scopus
  233. E. J. Hartsough, R. D. Meyer, V. Chitalia et al., “Lysine methylation promotes VEGFR-2 activation and angiogenesis,” Science Signaling, vol. 6, no. 304, Article ID ra104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  234. N. Rahimi and C. E. Costello, “Emerging roles of post-translational modifications in signal transduction and angiogenesis,” Proteomics, vol. 15, no. 2-3, pp. 300–309, 2015. View at Publisher · View at Google Scholar · View at Scopus